Skip to content
HowShorted

LIGAND PHARMACEUTICALS INC short interest in 2024

In 2024, LIGAND PHARMACEUTICALS INC's disclosed short interest ran from 5.28% of shares outstanding on 12 Jan 2024 to 4.76% on 31 Dec 2024, a change of -0.52 percentage points. The year's high was 6.12% on 15 Jul 2024 and its low 3.80% on 28 Mar 2024, averaging 4.95% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.64 days on 15 Oct 2024. Full history: LIGAND PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for LIGAND PHARMACEUTICALS INC in 2024

2024 in figures

Start of year
5.28% (12 Jan 2024)
End of year
4.76% (31 Dec 2024)
Change
-0.52 pp
High
6.12% (15 Jul 2024)
Low
3.80% (28 Mar 2024)
Average
4.95%
Highest days to cover
13.64 (15 Oct 2024)
SEC filings marked
8

Every report in 2024

LIGAND PHARMACEUTICALS INC short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20245.28%7.95
31 Jan 20245.33%10.52
15 Feb 20245.14%7.44
29 Feb 20244.31%3.20results (8-K), 10-K filed
15 Mar 20244.95%3.37
28 Mar 20243.80%5.54
15 Apr 20244.67%5.06
30 Apr 20244.49%5.36
15 May 20244.78%4.73results (8-K), 10-Q filed
31 May 20243.94%5.80
14 Jun 20245.21%8.34
28 Jun 20245.20%7.56
15 Jul 20246.12%6.99
31 Jul 20245.35%7.89
15 Aug 20245.82%7.93results (8-K), 10-Q filed
30 Aug 20245.45%9.48
13 Sep 20245.35%12.25
30 Sep 20245.45%9.06
15 Oct 20245.49%13.64
31 Oct 20245.03%8.92
15 Nov 20244.40%5.02results (8-K), 10-Q filed
29 Nov 20244.16%6.96
13 Dec 20244.30%7.69
31 Dec 20244.76%5.93

See also: LIGAND PHARMACEUTICALS INC's full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.